In three MYD88WT-expressing DLBCL cell lines used as a control, neither baseline MYD88/IRAK/TRAF6 complex formation nor constitutive downstream TAK1 phosphorylation was detected, suggesting that MYD88L265P but not MYD88WT is associated with constitutive activation of intracellular signaling through TAK1. Here, TRAF6 is linked to diffuse large B-cell lymphoma.